MONOPAR THERAPEUTICS INC

Insider buys Monopar Therapeutics shares at $30 and $14 – deep discounts to $113.94 – while selling for $111‑113, showing a balanced, risk‑managed strategy.

Monopar Therapeutics insider moves reveal a balanced long‑term strategy, combining ADC innovation, pricing tactics, and robust funding to drive oncology success.

Monopar Therapeutics’ CFO’s new stock purchase signals strong insider confidence and bolsters the oncology pipeline’s growth potential, offering a promising outlook for long‑term investors.